Subsidy Information and Financing Scheme MAFBurosumab (Crysvita) Solution For Injection 10 mg/mL, 20 mg/mL, and 30 mg/mL Additional clinical criteria applies Treatment of X-linked hypophosphataemia (XLH) in adults and c... See all × MAFBurosumab (Crysvita) Solution For Injection 10 mg/mL, 20 mg/mL, and 30 mg/mL Additional clinical criteria applies Treatment of X-linked hypophosphataemia (XLH) in adults and children 1 year of age and older.
Drug Guidance for Subsidy 04/06/2024 Burosumab for treating X-linked hypophosphataemia The Ministry of Health’s Drug Advisory Committee has recommended: Burosumab 10 mg/mL, 20 mg/m... See all × 04/06/2024 Burosumab for treating X-linked hypophosphataemia The Ministry of Health’s Drug Advisory Committee has recommended: Burosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection for treating X-linked hypophosphataemia (XLH) in adults and children 1 year of age and older, in line with the following criteria: Patient must have a documented confirmation of PHEX pathogenic variant; or Patient must have a confirmed diagnosis of XLH demonstrated by the presence of all of the following: a serum phosphate concentration below the age adjusted lower limit of normal; current or historical (for those with growth plate fusion) radiographic X-ray evidence of rickets; renal phosphate wasting demonstrated by a ratio of tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) according to age specific normal ranges using the second morning urine void and paired serum sample measuring phosphate and creatinine; and Patient must be treated by, or in consultation with, a specialist physician experienced in the diagnosis and management of XLH. Funding status RBurosumab 10 mg/mL, 20 mg/mL and 30 mg/mL solution for injection are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.
SUBCUTANEOUS Select a brand starting with the letter: C CRYSVITA® SOLUTION FOR INJECTION 10 MG/ML [SIN16178P] CRYSVITA® SOLUTION FOR INJECTION 20 MG/ML [SIN16176P] CRYSVITA® SOLUTION FOR INJECTION 30 MG/ML [SIN16177P]